Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Macular Degeneration: early-phase trial registry
5 of 28 indexed Macular Degeneration trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #577 of 28,707 conditions by registered trial count.
28 US clinical trials · 5 currently recruiting · #577 of 28,707 conditions by registered trial count
Macular Degeneration: 28 US clinical trials tracked, 5 recruiting.
Macular Degeneration is the subject of 28 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is National Eye Institute (NEI), running 5 of these trials.
Enrollment posture brief
Registry condition macular-degeneration
OPEN 5 | RECR 18% | LATE 6 | EARLY 12 | RANK #577 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Acute Myelogenous Leukemia (18% recruiting · 39 trials)
Macular Degeneration lists 5 open slots (18% of 28 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Macular Degeneration on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Macular Degeneration is recruiting below its size-band peers.
5 of 28 indexed trials (17.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Macular Degeneration research.
National Eye Institute (NEI) accounts for 5 of 28 trials (17.9%). 22 distinct sponsors appear on at least one study for this condition label.
-
Typical Macular Degeneration enrolment sits around 60 participants.
Median target enrolment is 60 among the 27 trials that report a genuine target (sentinel values excluded). 16 of those (59.3%) plan for fewer than 100 participants.
-
Macular Degeneration research is mostly interventional.
22 interventional and 6 observational studies make up this index (78.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
28 total, page 1 of 1
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Astellas Pharma Global Development
NCT06779773
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Janssen Research & Development
NCT06635148
Factors in Learning And Plasticity: Macular Degeneration
University of Alabama at Birmingham
NCT05454124
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
Nanoscope Therapeutics
NCT06805474
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
MediBeacon
NCT04008121
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Aviceda Therapeutics
NCT05839041
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
Complement Therapeutics
NCT05797896
Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
Hoffmann-La Roche
NCT04567303
Factors in Learning And Plasticity: Healthy Vision
University of Alabama at Birmingham
NCT05439759
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
Regeneron Pharmaceuticals
NCT00509795
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
Alcon Research
NCT00299507
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
VA Office of Research and Development
NCT01115231
A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
Oregon Health and Science University
NCT00469352
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
National Eye Institute (NEI)
NCT00101764
Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)
Guardion Health Sciences
NCT03946085
High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration
National Eye Institute (NEI)
NCT00656903
A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
TargeGen
NCT00414999
Cooling Anesthesia for Intravitreal Injection
Recens Medical
NCT03732287
The Focal Electro-Oculogram in Macular Disease
National Eye Institute (NEI)
NCT02225119
A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers
GlaxoSmithKline
NCT01072214
Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration
National Eye Institute (NEI)
NCT00100009
Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
Retinal Consultants Medical Group
NCT00426998
Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection
Lahey Clinic
NCT00769392
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
Allergan
NCT02181517
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
Pfizer
NCT01003691
Identification and Treatment of Feeder Vessels in Macular Degeneration
National Eye Institute (NEI)
NCT00018070
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
Novartis Pharmaceuticals
NCT03954626
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
Alcon Research
NCT00058994
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 4 |
| Phase 3 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Macular Degeneration records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Macular Degeneration trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Macular Degeneration page
28 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Macular Degeneration trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Eye Institute (NEI) sponsors the most Macular Degeneration trials on record, review their full trial history before evaluating a specific study. See National Eye Institute (NEI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Macular Degeneration condition card totals 28 registered trials; most-linked intervention Ranibizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.